Sequencing of reverse-transcriptase genes and recombinant virus assays were performed on paired isolates from antiretroviral drug-naive patients randomized to stavudine and didanosine (group 1; ) or zidovudine and lamivudine (group 2; ) at baseline and after у12 n p 21 n p 21 months of follow-up. The T215Y mutation emerged in 13 (61.9%) and 2 (9.5%) isolates in groups 1 and 2, respectively ( ). Furthermore, in group 1, mutations associated with multi-P ! .0001 dideoxynucleoside resistance were selected in 3 isolates. In group 2, all isolates carried the M184V mutation. The median fold changes in susceptibilities to zidovudine, stavudine, and lamivudine were 16.4 and 1, 2.2 and 0.6, and 4.5 and 138 in groups 1 and 2, respectively ( , all P ! .0001 comparisons). These results suggest that the combination of stavudine and didanosine is associated more frequently with the emergence of zidovudine resistance and a decrease in susceptibility to stavudine than the combination of zidovudine and lamivudine.
to 24 weeks of stavudine plus didanosine (group 1;
), zidon p 51 vudine plus lamivudine (group 2;
), or an alternating regin p 51 men of both combinations ( ) [2] . At the end of the original n p 49 study, a long-term follow-up was initiated up to month 30, with sequential plasma sampling every 12 weeks. The decision to change the antiretroviral regimen was left to the discretion of the treating physicians. Patients from groups 1 and 2 who continued to receive randomized treatment for 112 months and in whom virologic failure (defined as plasma HIV-1 RNA levels 1200 copies/mL on 2 consecutive measures) was observed during therapy were enrolled in this study.
Resistance testing. Resistance testing was performed on paired HIV-1 isolates obtained at baseline and during follow-up at the latest time point available before therapy was changed. Genotyping resistance testing also was done at week 24 in all patients. In total, 42 patients (21 in each group) were studied. Other patients were not included in this study, because they were lost to follow-up, changed their antiretroviral treatment before month 12, or maintained a plasma HIV-1 RNA level !200 copies/mL, or because results of resistance tests were not available for technical reasons.
RT genotypic analysis. HIV-1 RNA was purified from plasma, and genotypic analysis was performed by use of the TruGene HIV-1 assay (Visible Genetics) or with the consensus method of the ANRS [3] . Reaction products were analyzed on an ABI Prism 377 automatic sequencing system, and mutations associated with NRTI resistance were identified, according to the consensus statement from the International AIDS Society Resistance-USA Panel [1] . Both techniques were equally accurate for sequencing, and mutants were detected if present in 25% of the viral population (D. Descamps, Laboratory of Virology, Hô pital Bichat, Paris, personal communication).
Phenotypic analysis.
Phenotypic resistance tests were per- formed on the same plasma samples that were used for genotypic analysis. Phenotypic resistance tests used a single cycle recombinant virus assay (Phenoscript; Viralliance) [4] . A resistance index (RI) was calculated as the ratio of the IC 50 for the tested sample to the IC 50 obtained for pNL 4-3 wild-type HIV-1 tested in parallel. Statistical analysis. We used the x 2 test or Fisher's exact test to compare groups. Quantitative variables summarized by mean values were compared using Student's t test. Variables summarized by median values were compared by Wilcoxon rank sum test. All statistical analyses were done with Stata software (version 6.0). Table 1 shows the characteristics of the 42 patients enrolled in this study. Baseline median plasma HIV-1 RNA levels and CD4 cell counts were lower in group 1, and virologic failure occurred significantly earlier in group 2. Therefore, the median duration of viral replication under treatment was significantly shorter in group 1 than in group 2 (4.6 vs. 18 months, respectively;
Results

Patients.
). P p .0002 RT genotypic analyses. In group 1, only 1 virus carried both M41L and T215D mutations at baseline. At week 24, 2 isolates carried the T215Y mutations. At follow-up, other thymidine-associated mutations (TAMs) had emerged. Overall, TAMs emerged in 14 isolates (66.7%), with the T215Y mutation present in 13 isolates (61.9%), either alone ( ) or associated n p 3 with M41L ϩ/Ϫ D67N, K70R, L210W, or K219E mutations ( ). One virus carried D67N, K70R and K219E mutations n p 10 associated with a new P157A mutation. Multidideoxynucleoside resistance (MDR) mutations (Q151M complex) emerged in 3 isolates (14.3%). The V75T mutation was detected twice, alone or associated with T215Y and M41L mutations. We did not observe any L74V mutation or any insertion. Only 3 isolates remained free of mutations.
In group 2, the only resistance mutation noted at baseline was 1 T69N mutation, which persisted during follow-up. M184V mutations emerged in all follow-up isolates at week 24. No T215Y mutation was detected at that time. The T215Y mutation emerged in only 2 cases (9.5%) at follow-up, either alone or associated with the M41L mutation. Other TAMs were M41L ( ), K70R ( ), and D67N plus K70R ( ). n p 4 n p 3 n p 3 No MDR mutation or insertion was observed in this group. The emergence of the T215Y mutation was significantly more frequent in group 1 than in group 2 (61.9% vs. 9.5%, respectively;
), and the emergence of the M184V mutation P p .0004 was significantly more frequent in group 2 than in group 1 (100% vs. 0%, respectively;
). P ! .0001 Phenotypic drug susceptibility. At baseline, no phenotypic resistance to any of the 5 tested NRTIs was detected in any sample. Table 2 shows the median changes in RIs to all 5 NRTIs tested among the 2 patient groups at follow-up. The observed changes in RI from baseline to follow-up were significantly different between groups 1 and 2 for zidovudine (16.4 vs. 1;
) and stavudine (2.2 vs. 0.6; ). Also, the in-P ! .0001 P ! .0001 crease in median RI to lamivudine was significantly greater in group 2 than in group 1 (138 vs. 4.5;
). No significant P ! .0001 differences were noted for didanosine or abacavir.
Associations between phenotypic and genotypic data. At baseline, all viruses were susceptible to the 5 tested NRTIs, including the one carrying both M41L and T215D mutations. In group 1 at follow-up, wild-type viruses were susceptible to the 5 NRTIs tested. The isolate with a single V75T mutation displayed a 2-fold increase in RI to stavudine and didanosine. In contrast, the combination of T215Y plus M41L mutations always was associated with a high RI to zidovudine and with a small increase in RI for the other NRTIs tested. Isolates with MDR mutations displayed high RIs to zidovudine, stavudine, didanosine, and abacavir. Of interest, the isolate carrying the D67N, K70R, K219E, and P157A mutations exhibited a "resistant" phenotypic pattern with RIs to zidovudine, lamivudine, stavudine, didanosine, and abacavir of 65, 138, 18.4, 6.6, and 4.3, respectively. In group 2, all follow-up isolates carried the M184V mutation and displayed a high RI (138) to lamivudine. The only isolate in this group with a decreased susceptibility to zidovudine carried both T215F and M41L mutations. No change in susceptibility to zidovudine was noted among isolates with a single T215Y mutation or other TAMs.
Discussion
We studied genotypic and phenotypic resistance patterns of HIV-1 isolates from 42 patients who received initial antiretroviral therapy with combinations of either stavudine and didanosine (group 1) or zidovudine and lamivudine (group 2) for у12 months and who experienced treatment failure. Despite lower baseline plasma HIV-1 RNA levels and later occurrence of viral failure in group 1, genotypic and phenotypic resistance to zidovudine was significantly more frequent in that group.
Other studies of antiretroviral drug-naive patients treated with a combination of stavudine plus didanosine also have reported the emergence of zidovudine-associated mutations. Coakley et al. [5] noted that a mutation at codon 215 emerged in 7 (19.4%) of 36 paired isolates from patients treated for a median of 52 weeks. Pellegrin et al. [6] reported that codon 215 mutations emerged in 9 (23%) of 39 patients treated for a mean of 41 weeks [6] . The higher frequency of genotypic resistance observed in this report (61.9%) probably is related to the longer patient follow-up (19 months). Conversely, the rare emergence of the T215Y mutation in patients receiving a combination of zidovudine and lamivudine is striking. It is remarkable that this combination selected merely 2 T215Y mutations and only 1 phenotypically zidovudine-resistant isolate, although viral replication had been ongoing for a median of 18 months before resistance testing. A similar low frequency (19%) of T215Y mutations was reported in patients receiving zidovudine plus lamivudine as initial therapy [7] .
One explanation for the difference between the groups could be the protective effect of the M184V mutation on the emergence of other zidovudine-associated mutations [8] . Several other mechanisms have been proposed to account for this phenomenon, including reduced fitness of lamivudine-resistant virus and enhanced fidelity of the M184V RT [9, 10] . Further studies are needed to confirm this hypothesis.
It is clear that the MDR mutations (151 complex) initially described after zidovudine plus didanosine or zidovudine plus dideoxycytidine regimens can be selected by other nucleoside analogue combinations. Of note, MDR mutations were found in the 3 studies (including ours) in which antiretroviral drugnaive patients were treated with a combination of stavudine plus didanosine [5, 6] .
In group 1, only 2 isolates carried the V75T mutation, which can confer resistance to stavudine in vitro but is rare in clinical practice [11] . We found a significant 2.2-fold decrease in susceptibility to stavudine in follow-up isolates derived from patients in group 1. This modest in vitro shift in phenotypic susceptibility might be clinically relevant, since recent data suggest that isolates with a phenotypic RI 11.8 might not be sensitive to stavudine in vivo [12] . Our finding is supported by the similar (1.9) in vitro decrease in stavudine susceptibility reported by Coakley et al. [5] in patients receiving the same dual nucleoside combination. Those patients were assessed by a peripheral blood mononuclear cell-based assay. This finding also is supported by the growing body of evidence that TAM-bearing isolates are associated with reduced in vivo susceptibility to stavudine and that cross-resistance between zidovudine and stavudine, 2 thymidine analogues, is more extensive than previously thought [13, 14] . We observed a modest but significant increase in susceptibility to stavudine in follow-up isolates of patients in group 2, the role of which is currently unknown.
We noted a "small" decrease in susceptibility to didanosine in both patient groups at follow-up. The impact of these low levels of phenotypic resistance in vivo is not known; however, a recent report suggests that TAMs could be associated with a lesser in vivo response to didanosine, and previous reports have shown some degree of cross-resistance between didanosine and lamivudine [13] .
Of interest, 1 isolate with high-level phenotypic resistance to zidovudine, lamivudine, and stavudine emerged in group 1 but did not carry any MDR complex mutations. Instead, the D67N, L70R, and K219E mutations were identified, in addition to a new P157A substitution that was not present at baseline. A P157S mutation was reported to induce a 5-fold decreased susceptibility to lamivudine in vitro [15] .
Overall, our results show that, in patients who experience treatment failure while receiving stavudine plus didanosine, the emergence of genotypic and phenotypic resistance to zidovudine and potentially to stavudine is more frequent than in persons receiving zidovudine plus lamivudine. Although it is difficult to know how these results could be generalized in highly active antiretroviral therapy regimens, they may suggest that, in patients receiving a combination of stavudine and didanosine, antiretroviral therapy should be changed as soon as viral replication is no longer fully suppressed, to avoid the emergence of cross-resistance to other NRTIs. Our study also showed a need to better delineate the clinical relevance of even small increases in resistance levels, as measured in culture-based phenotypic assays, and to define cutoffs that would be accurate predictors of the in vivo response.
